clinical trial · NCT06613698
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
Liver Diseases, AlcoholicGSK4532990Placebo
brief summary
The goal of this study is to assess the safety and efficacy of GSK4532990 in participants with alcohol-related liver disease.
started
Sep 27, 2024
primary completion
Nov 26, 2027
completion
Mar 7, 2028
last updated
Aug 3, 2026
official title
A Dose-Finding, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of GSK4532990 for Steatohepatitis in Adults With Alcohol-related Liver Disease (ALD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol